NanoString Launches the Most Comprehensive Spatial Proteomics Panel Ever Offered
September 13 2023 - 6:00AM
Business Wire
Empowering researchers to spatially profile
more than 500 proteins simultaneously in FFPE tissue using abcam’s
IHC-validated immuno-oncology antibody portfolio
NanoString Technologies (NASDAQ:NSTG), a leading provider of
life science tools for discovery and translational research,
announced today the launch of the latest assay for the GeoMx®
Digital Spatial Profiler (DSP). The GeoMx IO Proteome Atlas (IPA)
is the industry’s most comprehensive spatial proteomics assay,
enabling spatial profiling of more than 500 immuno-oncology (IO)
relevant targets from FFPE (Formalin-Fixed, Paraffin-Embedded)
tissue sections.
Containing IHC-compatible antibodies entirely from abcam’s
extensive IO portfolio, the GeoMx IPA provides an extraordinary
advancement in the field of spatial proteomics. The assay will
provide researchers with more than five times the content of any
competing panel, offering access to unprecedented power. Its
utility is applicable to the search for novel biomarkers and drug
targets, investigating therapeutic response, stratifying patients,
and determining drug mechanisms of action.
“The GeoMx IPA represents the convergence of two of the most
dynamic fields in biomedical research: spatial biology and
high-plex proteomics,” said Brad Gray, President and CEO of
NanoString. “And with abcam providing the content, users get access
to a broad range of high-quality recombinant IO antibodies in a
single assay. When the IO Proteome Atlas is used in combination
with our popular Whole Transcriptome Atlas (WTA), GeoMx DSP becomes
by far the most powerful spatial profiler available.”
The combination of NanoString’s GeoMx IPA and WTA offers
researchers unprecedented levels of data in the largest ever
spatial proteomic panel of its kind. The panel leverages the unique
capabilities of GeoMx DSP to non-destructively and quantitatively
profile protein expression over five logs of dynamic range in
distinct compartments such as the tumor, stroma, and immune
contexture. Researchers can run GeoMx IPA as a standalone assay or
in conjunction with GeoMx WTA and can even layer GeoMx IPA data
with previously collected WTA data to easily analyze the two
datasets.
“We are excited to partner with NanoString on this
first-of-its-kind assay for high-plex spatial proteomics of FFPE,”
said Alejandra Solache, SVP, R&D at abcam. “By contributing to
the GeoMx IO Proteome Atlas we’re able to make abcam’s broad
portfolio of precision antibodies for IO research available to
researchers in a cutting-edge spatial biology product that will
help enhance our understanding of cancer immunology and accelerate
novel discoveries.”
The launch of the GeoMx IPA is the latest development in a
long-standing collaboration between NanoString and abcam to provide
high-quality, validated antibodies for use with NanoString’s
spatial analysis platforms. Most recently, NanoString and abcam
announced the inclusion of abcam-validated antibodies in the first
64-plex panel for NanoString’s CosMx™ Spatial Molecular Imager.
Although the content is targeted for IO research, GeoMx IPA has
broad applicability beyond cancer, including research areas such as
infectious disease, organ transplant, autoimmunity, metabolism, and
epigenetics.
The GeoMx IPA assay can enable researchers to:
- Spatially profile FFPE tissue using over 500 of abcam’s
IHC-validated IO antibodies in a single assay, simplifying the
search for new protein biomarkers and drug targets with unrivaled
plex. Antibodies can also be used individually for further single
target or lower plex investigation.
- Obtain more comprehensive biological information from
precious tissue samples than traditional immunohistochemistry
(IHC) or immunofluorescence (IF) assays.
- Discover novel IO drug targets by profiling the
expression of over 500 protein targets from a single FFPE tissue
section.
- Profile the whole human transcriptome and IO proteome from a
single slide by combining GeoMx IPA with GeoMx WTA for
same-slide spatial proteogenomic analysis.
The GeoMx IPA assay is available now for pre-order with
shipments expected to begin in Q4 2023.
About NanoString Technologies, Inc.
NanoString Technologies, a leader in spatial biology, offers an
ecosystem of innovative discovery and translational research
solutions, empowering our customers to map the universe of biology.
The GeoMx® Digital Spatial Profiler is a flexible and consistent
solution combining the power of whole tissue imaging with gene
expression and protein data for spatial whole transcriptomics and
proteomics. The CosMx™ Spatial Molecular Imager is a single-cell
imaging platform powered by spatial multiomics enabling researchers
to map single cells in their native environments to extract deep
biological insights and novel discoveries from one experiment. The
AtoMx™ Spatial Informatics Platform is a cloud-based informatics
solution with advanced analytics and global collaboration
capabilities, enabling powerful spatial biology insights anytime,
anywhere. At the foundation of our research tools is our nCounter®
Analysis System, which offers a secure way to easily profile the
expression of hundreds of genes, proteins, miRNAs, or copy number
variations, simultaneously with high sensitivity and precision. For
more information, visit www.nanostring.com.
The NanoString logo, NanoString, NanoString Technologies, GeoMx,
CosMx and nCounter are trademarks or registered trademarks of
NanoString Technologies, Inc., in the United States and/or other
countries.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230913107981/en/
Doug Farrell, NanoString Vice President, Investor Relations
& Corporate Communications dfarrell@nanostring.com Phone:
206-602-1768
NanoString Technologies (NASDAQ:NSTG)
Historical Stock Chart
From Apr 2024 to May 2024
NanoString Technologies (NASDAQ:NSTG)
Historical Stock Chart
From May 2023 to May 2024